Treatment adherence (defined as dose delay) ( · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Treatment adherence (defined as dose reduction) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · women with early poor prognosis breast cancer
High‐dose chemotherapy leads to higher treatment‐related mortality compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Shoulder range of motion for abduction ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Shoulder range of motion for forward flexion ‐ short term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Shoulder range of motion for forward flexion ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Shoulder range of motion for external rotation ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Shoulder range of motion for internal rotation ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Lymphoedema ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
It is very uncertain whether early shoulder mobilising exercises changes lymphoedema ‐ medium term compared with delayed shoulder mobilising exercises (very low certainty).
1 finding from 1 review
Shoulder range of motion for abduction ‐ short term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Safety of systemic therapies for the treatment of AIMSS · health problem or population
1 finding from 1 review
Overall survival: Median length of · women with early breast cancer
OFS leads to lower overall survival (OS) Median compared with no OFS (high certainty).
1 finding from 1 review
Disease-free survival · women with early breast cancer
OFS leads to lower disease‐free survival (DFS) Median compared with no OFS (high certainty).
1 finding from 1 review
Toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade" toxicity) · women with early breast cancer
OFS may leads to higher toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade"… compared with no OFS (low certainty).
1 finding from 1 review
Toxicity ‐ mood · women with early breast cancer
1 finding from 1 review
Toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) · women with early breast cancer
OFS may leads to higher toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) compared with no OFS (low certainty).
1 finding from 1 review
Contralateral breast cancer · women with early breast cancer
OFS probably leads to lower contralateral breast cancer compared with no OFS (moderate certainty).
1 finding from 1 review
Quality of life · women with early breast cancer
1 finding from 1 review
Overall survival · women with early breast cancer
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Disease‐free progression · women with early breast cancer
Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review